A biotech company has launched a dielectric fluid for liquid-cooled data center systems.Trinity Biotech, a Nasdaq-listed biotechnology company focused on human diagnostics and diabetes management solutions, this week announced the launch of Trinovium, a dedicated subsidiary focused on liquid cooling solutions and fluid intelligence systems for AI data centers.Trinity said Trinovium will leverage the parent company’s “expertise in ultra-high-purity fluid manufacturing, analytical technologies, and large-scale production capabilities to address the growing reliability challenges associated with next-generation liquid cooling systems.”Trinovium has reportedly developed an initial direct-to-chip liquid cooling formulation. Full details haven't been shared.The firm is also working on a fluid health and system intelligence platform, based on its analytical technology portfolio, including connected electrochemical sensing and mass spectrometry capabilities. The platform is being designed to monitor corrosion and scaling, particulate contamination, microbial growth, and biofilm formation.Trinity said it would be able to redirect a portion of its existing United States and European Union manufacturing capacity – capable of producing millions of liters of high-precision fluids annually – to support Trinovium.“This strategy expands our capabilities into one of the most important infrastructure layers underpinning AI and builds upon our work developing AI-powered diagnostics,” said John Gillard, CEO of Trinity Biotech. “We are leveraging what we do today at an exceptionally high standard, manufacturing ultra-high purity, highly stable fluids, and applying it to AI infrastructure – one of the fastest-growing segments of global compute and a market where performance, reliability, and quality are increasingly mission-critical.”Founded in 1992 and based in Ireland, Trinity has traditionally been focused on developing diagnostic systems for the point-of-care and clinical laboratory segments. Its products include testing systems for HIV, prostate cancer, diabetes, and various other conditions.Gillard continued: “We believe Trinovium positions Trinity Biotech as an emerging AI infrastructure enabler, not just as a supplier, but as a partner helping customers maximize system performance. With a capital-efficient entry point, exposure to a rapidly scaling market with faster innovation cycles than healthcare, and a recurring analytics layer, this initiative has the potential to materially and rapidly reshape how Trinity Biotech is positioned and valued.”